ESR1 and breast carcinoma: Evidence from ER-BMET models, which represent the majority of preclinical breast cancer BMET research, has allowed for an assessment of the influence of estrogenic effects on the bone microenvironment, independent of tumor cell ER signaling, on osteolytic ER− BMET progression.